Will artificial intelligence solve the drug discovery productivity crisis?

Date
530pm - 830pm
Location
12790 El Camino Real- San Diego, CA 92130

Will artificial intelligence solve the drug discovery productivity crisis?

There needs to be a fundamental shift in drug discovery, and artificial intelligence may be the key to bringing the pharma industry into the 21st century. Drug makers and tech companies are investing billions of dollars in artificial intelligence with the hope that AI will make the drug discovery process faster and cheaper. From designing better compounds to targeting the correct patients for clinical trials, machine learning and advanced algorithms may be utilized to increase the speed and success of drug development. As many as 74% of life science executives believe that AI will result in significant change or even completely transform their industry within 3 years.

However, not everyone is convinced that AI will transform drug development. There is caution until the true power of these technologies is completely understood, concern that AI is “over-hyped,” and skepticism among the public about its value. This program will provide new insights and experiences on how to move away from the hype. Innovators and entrepreneurs from some of the hottest companies in the field will present real world case studies based on the latest science demonstrating how to harness AI and ML to transform aspects of the life sciences industry, from R&D through personalized medicine. This is followed by an interactive panel discussion around the current state of the field, regulatory and other development hurdles, and what the future of AI and ML in drug discovery holds.

MODERATOR:

Attila Hajdu, MBA, MSc, CEO, Stelvio Therapeutics

PANELISTS

Bryan Walker, Ph.D., Founder and CEO, Animantis, La Jolla, CA
Janusz Dutkowski, Ph.D., CEO and Co-Founder, Data4Cure, San Diego, CA
Jasna Delic, Partnering Executive, Atomwise, San Francisco, CA
Navid Alipour, JD/MBA, Co-Founder, Managing Partner, Analytics Ventures, La Jolla, CA
Casey Laris, Co-Founder and CTO, Reveal Biosciences, San Diego, CA

AGENDA

5:30: Registration, Networking, food and drinks
6:30: Panel discussion
7:30: Audience Q & A
8:00: Program Concludes, Networking, Coffee & Dessert until 8:30

WHO SHOULD ATTEND

This event is of value for everyone working in the life science industry. It is especially relevant for individuals in drug discovery in academia, research institutes, and industry. Also, drug development, bioinformatics, machine learning, artificial intelligence, venture capital, and start-ups.

FEES:

$35 l Early Bird through May 12
$45 l General Registration
$25 l Student
$55 l Day of Event

LOCATION:

Knobbe Martens
12790 El Camino Real
San Diego, CA 92130

SPEAKERS' BIOGRAPHIES

Attila Hajdu, MBA, MSc, CEO, Stelvio Therapeutics

Stelvio Therapeutics, a JLABS San Diego resident company, is developing novel therapeutics for glioblastoma through an epigenetics live imaging-based platform that is deeply rooted in machine learning. Attila is an experienced executive with 17 years’ experience in big pharma (GSK, Astellas) and biotechnology (Sirona Biochem) in various senior leadership roles in sales, marketing, finance, clinical development, medical affairs and business development. His passion is successfully delivering innovative solutions for unmet needs.

Bryan Walker, Ph.D., Founder and CEO, Animantis

Bryan is the founder and CEO of Animantis, an early stage company that has developed an AI-based drug discovery platform focused on modeling complex cellular behaviors and interactions to better predict drug efficacy. As CEO, Bryan has been responsible for developing the overall strategy for the company, securing financing, and engaging pharmaceutical and academic partners leveraging Animantis’ proprietary platform. Prior to founding Animantis in 2014, Bryan was a researcher at Yale University. During his time as a researcher at Yale, Bryan developed modular engineered tissue models to more effectively characterize primary innate immune cell function in vitro. Bryan graduated from Yale University with a B.S. in Biomedical Engineering in 2013.

Janusz Dutkowski, Ph.D., CEO and Co-Founder, Data4Cure

Janusz Dutkowski is Co-founder and CEO of Data4Cure, Inc. – a company focused on combining systems biology, machine learning and AI to facilitate continuous translation of biomedical data to knowledge. His background is in mathematics and computer science. For the last 15 years he has been working at the intersection of mathematics, computer science and biology to develop new data-driven technologies to advance the discovery of new biomarkers and precision-based therapies. Before founding Data4Cure he was a scientist at the University of California, San Diego where along with Dr. Trey Ideker he led the development of methods for multiscale analysis of molecular networks and integrative methods for biomarker discovery from multidimensional data. He has co-authored over 20 research papers published in scientific journals including Nature Biotechnology, Science and Cell.

Jasna Delic, Partnering Executive, Atomwise

Jasna is Partnering Executive at Atomwise. Atomwise develops artificial intelligence systems using powerful deep learning algorithms and supercomputers to shorten the process of discovering new drugs. In March 2018, Atomwise raised a $45 million Series A, bringing their total amount raised to $51 million. The company now has more than 50 molecular discovery programs.

Navid Alipour, JD/MBA, Co-Founder, Managing Partner, Analytics Ventures

Navid is Co-founder and Managing Partner at Analytics Ventures, a Venture Formation Fund focused on starting new ventures with Artificial Intelligence (AI) and Machine Learning (ML) at their core. Prior to co-founding Analytics Ventures, Navid founded La Costa Investment Group, making targeted investments in multiple AI based companies, bringing them from inception to success, including CureMetrix and Curematch. Navid serves on the Board of Tech San Diego where he is recognized for his role helping develop San Diego’s now thriving eco-system. He is also on the boards of CureMetrix, AV Lab, Kazuhm, AlphaTrAI, & AdTheos. He has been a panelist, judge, speaker and moderator at forums such as UCSD, USD, SDSU, CyberHive, HeraHub, MIT Forum, RSNA, U.S. News STEM Conference, and CONNECT. Navid holds a BA from UC San Diego, and a JD/MBA from the University of San Diego.

Casey Laris, Co-Founder and CTO, Reveal Biosciences

Casey Laris is Co-founder and CTO at Reveal Biosciences, a computational pathology company leveraging artificial intelligence (AI) to enable pathologists to make diagnostic decisions faster, more accurately, and for less money. Reveal has partnered with leading clinical pathology labs providing access to millions of patient pathology slides and data. This data has allowed them to develop a strong pipeline of highly accurate AI-based clinical diagnostics, with the first reaching the clinic in Q3 2018. Prior to co-founding Reveal, Casey spent 20 years in a variety of roles developing and analyzing big data sets from high throughput microscopes with the aim to improve diagnosis in the clinic. He has served in product and tech lead roles at UCSD, Sanford-Burnham MRI, Beckman Coulter, Accerlys and Vala Sciences. Casey holds a BS from UC San Diego. He believes that the use of AI in pathology will make a strong impact to patients both in the US and throughout the world.

For Sponsorship Opportunities Contact Teresa Gallagher, President, San Diego Clinical Research Network. Phone 858-692-1835. teresa@clinicalresearchcurrents.com

SPONSOR

Have questions about Artificial Intelligence & Machine Learning in Drug Discovery: Moving Beyond the Hype? Contact San Diego Clinical Research Network (SDCRN) and San Diego Biotechnology Network (SDBN)

San Diego Clinical Research Network (SDCRN) and San Diego Biotechnology Network (SDBN)
San Diego Clinical Research Network (SDCRN) provides educational programs for the life science community on emerging topics in clinical research and related areas. SDCRN also publishes a national clinical research newsletter, Clinical Research Currents. http://clinicalresearchcurrents.com/newsletter/.

For more information, contact Teresa Gallagher at teresa@clinicalresearchcurrents.com.

The San Diego Biotechnology Network (SDBN) is in its 10th year, amassing more than 20,000 life science followers who depend on it to improve their networking skills and stay updated on local and global biotechnology news and events. https://sdbn.org/about/

For more information, contact Mary Canady.

Wednesday, May 2, 2018- 5pm-7pm: CRO Networking Mixer

Date
5pm - 7pm
Location
Biocom Terrace- 10996 Torreyana Rd. Suite 200, San Diego, CA 92121

Biocom invites you to join us on Wednesday, May 2nd at The Alexandria at Torrey Pines (Biocom) for a hosted networking reception specially designed for our CRO Members. With over a hundred CRO’s in our membership, this is an opportunity to gain a better understanding of your colleagues expertise in order to foster more collaboration within the CRO Community. We invite you to enjoy hosted hors d'oeuvres and cocktails on the outdoor patio, while listening to a brief pitch about each participating CRO and the services they offer.

Thursday, April 19th, 2pm-4pm- South San Francisco-Modified Release Solid Oral Dosage Formulations and Regulatory Considerations

Date
2pm - 4pm
Location
Genesis Tower, One Tower Place, South San Francisco, CA 94080

Join Biocom and RECRO Gainesville for a seminar regarding "Modified Release Solid Oral Dosage Formulations and Regulatory Considerations." RECRO Gainesville is a CDMO pioneering the development of extended release technologies.

The presentations will review the technical formulation differences between immediate release and controlled (modified) release solid oral formulations with an emphasis on formulation approaches for modified release, including reasons for changing from immediate to modified release and how to go about this change from a technical perspective. Discussions will provide Regulatory considerations for Modified Release formulations including the most common regulatory pathways for approval with comparison and contrast for each option.

https://www.biocom.org/s/EventDetail?event=CRO-RECRO

Wednesday, April 18, 2018: Modified Release Solid Oral Dosage Formulations and Regulatory Considerations

Date
8am - 10am
Location
Biocom: McGraw Boardroom- 10996 Torreyana Rd. Suite 200, San Diego, CA 92121

Join Biocom and RECRO Gainesville for a seminar regarding "Modified Release Solid Oral Dosage Formulations and Regulatory Considerations." RECRO Gainesville is a CDMO pioneering the development of extended release technologies.

The presentations will review the technical formulation differences between Immediate release and Controlled (modified) release solid oral formulations with an emphasis on formulation approaches for Modified Release, including reasons for changing from immediate to modified release and how to go about this change from a technical perspective. Discussions will provide Regulatory considerations for Modified Release formulations including the most common regulatory pathways for approval with comparison and contrast for each option.

Speakers:
Dr. Myke Scoggins, Process Development manager at RECRO Gainesville, LLC.
R. Wayne Wiley, Senior Director of Regulatory Affairs at RECRO Gainesville LLC.

Thursday, April 12, 2018 in South Francisco -Humanized Mouse Models and Their Use in Preclinical Bone Metastasis Studies

Date
12pm - 2pm
Location
Larkspur Landing-690 Gateway Blvd. South San Francisco, CA 94080

Pharmatest Services and Taconic Biosciences welcome you to an educational seminar titled “Humanized Mouse Models and Their Use in Preclinical Bone Metastasis Studies." This seminar addresses In vivo models for immuno-oncology research and novel bone metastasis models in humanized mice.

Speakers:

Jussi Halleen, CEO, Pharmatest Services
Tiina Kähkönen, Research Director, Pharmatest Services
Azusa Tanaka, Product Manager for Precision Research Models, Taconic Biosciences

Agenda:

10:00 - 10:30am Registration and networking

10:30 - 10:45am Introduction by Jussi Halleen, CEO, Pharmatest Services

10:45 - 11:15am "In vivo Models for Immuno-Oncology Research: Human Immune System Engrafted Mouse Models," by Azusa Tanaka, Product Manager for Precision Research Models, Taconic Biosciences

11:15 - 11:45am "Novel Bone Metastasis Models in Humanized Mice," by Tiina Kähkönen, Research Director, Pharmatest Services

11:45 - 12:00pm Q&A

February 14, 2018: How to develop a clear and compliant clinical data submission strategy

Date
8am - 10am
Location
Biocom 10996 Torreyana Rd. Suite 200 San Diego, CA 92121

How to develop a clear and compliant clinical data submission strategy
Accenture’s Clinical Data Operations Director, Brian Hermann will host a seminar focusing on how to plan and prepare your clinical data for submission readiness within Module 5. The seminar discusses up-to-date information that will better prepare your company for the rigors of preparing your clinical data packages in accordance with current guidance. Learn how to develop a clear and compliant clinical data submission strategy based on studies showing where many companies struggle during the submission process.

Both early-stage companies who are new to the clinical data submission guidance’s, and portfolio builders who want to enhance their current clinical data submission knowledge, will benefit from attending the seminar.

We plan to cover the following topics:
• CDISC
• Recent binding guidance from FDA (effective Dec 2016)
o Waivers
o Exemptions
o Timelines
• Study Data Technical Conformance Guide
• Study Data Standardization Plan
• Data Traceability and the FDA
• Define files
• Reviewers guides
• Annotated CRFs
• Pinnacle21 Data Validation
• Coding
• Pooling
• Submission Timelines

Important Event Details
________________________________________
When: Wednesday, February 14th
8:00 a.m. - 10:00 a.m.

Where: Biocom (McGraw Boardroom)
10996 Torreyana Road
San Diego, California 92121

*This event is free for Biocom members

Tuesday, January 23, 2018-Humanized Mouse Models in Preclinical Efficacy Studies in Oncology

Date
8am - 10am
Location
Biocom, McGraw Boardroom, 10996 Torreyana Road Suite 200 San Diego, CA 92121
Download Presentation Download

Pharmatest Services and Crown Bioscience welcome everyone to an educational seminar titled “Humanized mouse models in preclinical efficacy studies in oncology”. Humanized mouse models include a functional human immune system, which allows the efficacy testing of immunotherapies on human cancer cells in immunocompetent mice. The seminar also discusses the importance of using preclinical metastasis models to confirm novel agent efficacy before entering clinical trials.

Speakers:
Jussi Halleen, CEO, Pharmatest
H. Toni Jun, Director Scientific Engagement, CrownBio
Mari Suominen, Research Director, Pharmatest

Tuesday, November 7th, 2017-Biocom CRO Networking Mixer

Date
5pm - 7pm
Location
Biocom-McGraw Boardroom- 10996 Torreyana Rd. Suite 200, San Diego CA 92121

Please join us on Tuesday, November 7th, from 5pm-7pm in the McGraw Boardroom at Biocom for a hosted CRO Networking Mixer specially designed for our CRO Members. With over a hundred CRO’s in our membership, this is an opportunity to gain a better understanding of your colleagues expertise in order to foster more collaboration within the CRO Community. We invite you to make valuable connections while enjoying hors d'oeuvres and cocktails, with the opportunity to share a brief pitch about your CRO’s unique offerings.

We look forward to seeing you then!